Cite
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
MLA
Hoffmann, Katrin, et al. “Impact of Neo-Adjuvant Sorafenib Treatment on Liver Transplantation in HCC Patients - a Prospective, Randomized, Double-Blind, Phase III Trial.” BMC Cancer, vol. 15, no. 1, May 2015, pp. 392–402. EBSCOhost, https://doi.org/10.1186/s12885-015-1373-z.
APA
Hoffmann, K., Ganten, T., Gotthardtp, D., Radeleff, B., Settmacher, U., Kollmar, O., Nadalin, S., Karapanagiotou-Schenkel, I., von Kalle, C., Jäger, D., Büchler, M. W., & Schemmer, P. (2015). Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer, 15(1), 392–402. https://doi.org/10.1186/s12885-015-1373-z
Chicago
Hoffmann, Katrin, Tom Ganten, Daniel Gotthardtp, Boris Radeleff, Utz Settmacher, Otto Kollmar, Silvio Nadalin, et al. 2015. “Impact of Neo-Adjuvant Sorafenib Treatment on Liver Transplantation in HCC Patients - a Prospective, Randomized, Double-Blind, Phase III Trial.” BMC Cancer 15 (1): 392–402. doi:10.1186/s12885-015-1373-z.